Quantum BioPharma (STU:0K91) Moat Score: 2/10 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0K91 Quantum BioPharma Ltd STU:0K91
38 GF Score
Price €2.64
! 5 Warning Signs
View Full Analysis

What is Quantum BioPharma Moat Score?

Quantum BioPharma STU:0K91 -6.84% 38 Moat Score is 2 as of Jul. 21, 2026. GuruFocus rates STU:0K91 with a GF Score™ of 38/100. The stock has 5 warning signs investors should review. Among 1,396 Biotechnology companies, Quantum BioPharma ranks better than 58.38% on this metric.

Quantum BioPharma has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Quantum BioPharma has No Moat: Quantum BioPharma Ltd lacks significant market leadership, customer loyalty, and durable cost advantages. Its intellectual property does not provide a strong competitive edge, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Quantum BioPharma might have No Moat - Very weak/transient advantages.

Quantum BioPharma  (STU:0K91) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Quantum BioPharma Moat Score Related Terms

STU:0K91 vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Quantum BioPharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quantum BioPharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quantum BioPharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Quantum BioPharma's Moat Score falls into.


STU:0K91
38GF Score
Quantum BioPharma Ltd STU:0K91
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Quantum BioPharma (STU:0K91) has a Moat Score of 2 as of Jul. 21, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Quantum BioPharma ranks #581 out of 1396 companies in the Biotechnology industry, placing it in the top 41.6%.
Is Quantum BioPharma's Moat Score too high?
Quantum BioPharma's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Quantum BioPharma's value of 2 is 0% at this industry median. Based on the distribution chart, Quantum BioPharma ranks #581 out of 1396 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Quantum BioPharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Quantum BioPharma's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Quantum BioPharma ranks #581 out of 1396 companies for Moat Score. This puts Quantum BioPharma in the upper half of its industry. The industry median Moat Score is 2.00. Quantum BioPharma's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quantum BioPharma's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quantum BioPharma's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quantum BioPharma stock overvalued right now?
Quantum BioPharma (STU:0K91) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Quantum BioPharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Quantum BioPharma (STU:0K91), the current Moat Score is 2 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quantum BioPharma Business Description

Other Exchanges QNTM:USAQNTM:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
38GF Score

Get the complete analysis for STU:0K91

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.64
Price